TIMMUNE BIOTECH INC has a total of 11 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2017. It filed its patents most often in WIPO (World Intellectual Property Organization), EPO (European Patent Office) and China. Its main competitors in its focus markets biotechnology, pharmaceuticals and measurement are LEGEND BIOTECH IRELAND LTD, WUHAN HEALTHGEN BIOTECHNOLOGY CORP and PRESTIGE BIOPHARMA PTE LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 8 | |
#2 | EPO (European Patent Office) | 2 | |
#3 | China | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Microorganisms | |
#3 | Medical preparations | |
#4 | Therapeutic chemical compounds | |
#5 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Gao Bin | 11 |
#2 | Wu Yasong | 6 |
#3 | Wei Qing | 5 |
#4 | Wang Lei | 5 |
#5 | Lv Lihui | 4 |
#6 | Gu Mingzhu | 4 |
#7 | Liu Ying | 4 |
#8 | Si Yuan | 4 |
#9 | Liang Meng | 3 |
#10 | Lv Dan | 3 |
Publication | Filing date | Title |
---|---|---|
WO2020043076A1 | Natural killer cell line silk-nk independent of cytokine culture | |
EP3575325A1 | Multi-target chimeric antigen receptor | |
WO2018121605A1 | Multifunctional protein | |
WO2018121602A1 | Protein function switch system controlled by small molecule drug | |
WO2018121474A1 | Single-domain antibody for identifying complex formed by hla-a2 molecule and rmfpnapyl short-chain polypeptide | |
WO2018121475A1 | Single-domain antibody recognizing complex formed by hla-a2 molecule and sllmwitqc short peptide | |
WO2018121476A1 | Single domain antibody which recognizes complex formed by hla-a2 molecule and nlvpmvatv short peptide | |
WO2018121473A1 | Single-domain antibody capable of recognizing human serum albumin |